Phathom Pharmaceuticals Begins Phase 2 Study Of VOQUEZNA For Eosinophilic Esophagitis Treatment

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company developing innovative treatments for gastrointestinal (GI) diseases, announced that the first patient has been dosed in its Phase 2 pHalcon-EoE-201 clinical trial. The study is evaluating VOQUEZNA® (vonoprazan) tablets as a potential treatment for eosinophilic esophagitis (EoE) in adults, a chronic inflammatory condition of the esophagus.

Steve Basta, President and CEO of Phathom, stated that the initiation of this trial underscores the company’s dedication to improving care for patients with GI disorders while exploring new therapeutic opportunities for VOQUEZNA. The data from this trial may also support future discussions about a pediatric program, which could extend the drug’s regulatory exclusivity and contribute to Phathom’s long-term growth strategy.

Dr. Evan S. Dellon, the study’s principal investigator, noted that despite progress in understanding EoE, current treatment options are limited. Proton pump inhibitors are commonly used but are not FDA-approved for EoE. VOQUEZNA’s strong acid suppression profile could offer a novel, oral, non-steroidal therapy for patients with this condition. The trial will enroll 80 adults in its first part, with participants randomized to receive VOQUEZNA or placebo for 12 weeks, followed by an optional 12-week extension phase. Results are expected in 2027.